Literature DB >> 12032141

Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone.

Sang Myun Park1, Han Young Jung, Thomas D Kim, Jeon Han Park, Chul-Hak Yang, Jongsun Kim.   

Abstract

alpha-Synuclein, an acidic neuronal protein of 140 amino acids, is extremely heat-resistant and is natively unfolded. Recent studies have demonstrated that alpha-synuclein has chaperone activity both in vitro and in vivo, and that this activity is lost upon removing its C-terminal acidic tail. However, the detailed mechanism of the chaperone action of alpha-synuclein remains unknown. In this study, we investigated the molecular mechanism of the chaperone action of alpha-synuclein by analyzing the roles of its N-terminal and C-terminal domains. The N-terminal domain (residues 1-95) was found to bind to substrate proteins to form high molecular weight complexes, whereas the C-terminal acidic tail (residues 96-140) appears to be primarily involved in solubilizing the high molecular weight complexes. Because the substrate-binding domain and the solubilizing domain for chaperone function are well separated in alpha-synuclein, the N-terminal-binding domain can be substituted by other proteins or peptides. Interestingly, the resultant engineered chaperone proteins appeared to display differential efficiency and specificity in terms of the chaperone function, which depended upon the nature of the binding domain. This finding implies that the C-terminal acidic tail of alpha-synuclein can be fused with other proteins or peptides to engineer synthetic chaperones for specific purposes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032141     DOI: 10.1074/jbc.M111971200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Stabilizing peptide fusion for solving the stability and solubility problems of therapeutic proteins.

Authors:  Eui Nam Lee; Young Mok Kim; Hye Ja Lee; Sang Woo Park; Han Young Jung; Jae Myun Lee; Yong-Ho Ahn; Jongsun Kim
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

2.  Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity.

Authors:  Sharareh Emadi; Hedieh Barkhordarian; Min S Wang; Philip Schulz; Michael R Sierks
Journal:  J Mol Biol       Date:  2007-03-07       Impact factor: 5.469

Review 3.  Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Authors:  G Brent Irvine; Omar M El-Agnaf; Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

4.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

Review 5.  Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Authors:  Dena A M Amer; G Brent Irvine; Omar M A El-Agnaf
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

Review 6.  Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.

Authors:  Heather E Allen Reish; David G Standaert
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

7.  Potassium depolarization and raised calcium induces α-synuclein aggregates.

Authors:  Jordan Follett; Bonnie Darlow; Mathew B Wong; Jacob Goodwin; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-12-19       Impact factor: 3.911

Review 8.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

9.  p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.

Authors:  Anuj Kumar Sharma; Amjad Ali; Rajan Gogna; Amir Kumar Singh; Uttam Pati
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

10.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.